- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- radiation therapy, cyclophosphamide, anti-thymocyte globulin, tacrolimus, methotrexate, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis
- Radiation · Drug · Biological + 2 more
- Lead sponsor
- Sumithira Vasu
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 1,385
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
- Interventions
- Antiandrogen Therapy, Axitinib, Radical Prostatectomy, Regional Lymph Node Dissection
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer
- Interventions
- Nexavar (Sorafenib, BAY43-9006), Bevacizumab, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Houston, Texas
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- Chlorambucil, Venetoclax, Obinutuzumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 445 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 8
- States / cities
- Gilbert, Arizona • Duarte, California • La Jolla, California + 5 more
- Conditions
- First Episode Psychosis
- Interventions
- Community Campaign La CLAVE
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 15 Years to 65 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Granada Hills, California
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Vosaroxin and Cytarabine
- Drug
- Lead sponsor
- Hamid Sayar
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- obinutuzumab, rituximab, chlorambucil
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 787 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 5
- States / cities
- San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more
- Conditions
- Mantle Cell Lymphoma, Untreated
- Interventions
- Lenalidomide, R-CHOP, high-dose cytarabine (HIDAC)
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Breast Cancer
- Interventions
- ARV-471, Anastrozole, Surgical resection of breast tumor
- Drug · Procedure
- Lead sponsor
- Arvinas Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 13
- States / cities
- Springdale, Arkansas • Los Angeles, California • Torrance, California + 10 more
- Conditions
- Sarcoma
- Interventions
- dactinomycin, filgrastim, pegfilgrastim, sargramostim, cyclophosphamide, irinotecan hydrochloride, vincristine sulfate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 49 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2009
- U.S. locations
- 209
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- cisplatin, etoposide, ifosfamide, lomustine, methotrexate, prednisone, vincristine sulfate
- Drug
- Lead sponsor
- German Society for Pediatric Oncology and Hematology GPOH gGmbH
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia
- Interventions
- Cytarabine, Daunorubicin, Etoposide, Topotecan
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 16 Years to 59 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2006
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Colorectal Cancer, Neoplasm Metastasis
- Interventions
- erlotinib, FOLFOX, bevacizumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Metastatic Childhood Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma
- Interventions
- Cixutumumab, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Temozolomide, Vincristine Sulfate Liposome
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 49 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more
- Conditions
- Waldenstrom's Macroglobulinemia
- Interventions
- Bortezomib, Rituximab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- First Episode Psychosis (FEP), Clinical High Risk for Psychosis (CHR)
- Interventions
- Screening Method (SM), Screening and Communication Method (SCM)
- Behavioral
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 12 Years to 30 Years
- Enrollment
- 912 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 26
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Sedona, Arizona + 23 more
- Conditions
- Hemophilia A
- Interventions
- Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- Up to 1 Year · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • New Brunswick, New Jersey
- Conditions
- Breast Cancer
- Interventions
- Imipramine
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 71 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Colorectal Cancer
- Interventions
- 5-FU, Bevacizumab, Folinic acid, Oxaliplatin, Vanucizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 11 more
- Conditions
- Leukemia
- Interventions
- asparaginase, cytarabine, daunorubicin hydrochloride, etoposide, gemtuzumab ozogamicin, mitoxantrone hydrochloride
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 29 Years
- Enrollment
- 1,070 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2020
- U.S. locations
- 178
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 141 more
- Conditions
- Pancreatic Cancer
- Interventions
- bevacizumab, cisplatin, gemcitabine hydrochloride
- Biological · Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- X-linked Myotubular Myopathy
- Interventions
- History and physical, Tidal breathing, Maximal respiratory pressures, Peak cough flow, Pediatric Evaluation of Disability Inventory, PedsQL Multidimensional Fatigue Scale, Review of ventilation requirements
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- Up to 14 Years · Male only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Rituximab Biosimilar, Prednisone, Prednisolone, Vincristine, Rescue medication, Methylprednisolone
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,046 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 61
- States / cities
- Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 56 more